Logo-jre

   
J Ren Endocrinol. 2023;9: e25099 | Published on: 2023 Jun 19. doi: 10.34172/jre.2023.25099

Mini-Review

Contrast-induced nephropathy; an update on pathophysiology

Yasaman Yadollahi Fars 1 ORCID, Razieh Moghadasi 1 ORCID, Shokouh Shayanpour 2 * ORCID

Cited by CrossRef: 3

1- Bahardoust M, Yarahmadi D, Aghakhani Z, Kakoienejad M, Shamohammadi M, Goodarzy B, Donyadideh G, Rashidi S, Ghaffari A. Comparison of Short-Term Treatment With Atorvastatin Versus Rosuvastatin for Preventing Contrast-Associated Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 2025;86(2):148 [Crossref]
2- Lee P, Huang S, Tsai Y, Wang Y, Chew F. Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies. IJMS. 2025;26(7):2869 [Crossref]
3- Samir A, Radwan A, Elhossary H, Baghdady Y. Predictive ability of serum osmolarity for contrast-induced nephropathy after elective percutaneous coronary intervention: Are we having a new target?. Egypt Heart J. 2025;77(1) [Crossref]
4- Mahmood K, Ewadh M, Al-Saad S. Assessment of cystatin C and CCL14 as predictive and diagnostic biomarkers for contrast-induced nephropathy . Regul Mech Biosyst. 2024;15(3):610 [Crossref]